Pages that link to "Q39882876"
Jump to navigation
Jump to search
The following pages link to On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. (Q39882876):
Displaying 50 items.
- Highly specific PET imaging of prostate tumors in mice with an iodine-124-labeled antibody fragment that targets phosphatidylserine (Q21132365) (← links)
- Challenges and opportunities for non-antibody scaffold drugs (Q26781607) (← links)
- Mapping biological behaviors by application of longer-lived positron emitting radionuclides (Q26824070) (← links)
- Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts (Q28535054) (← links)
- Mechanistic and quantitative insight into cell surface targeted molecular imaging agent design. (Q30383551) (← links)
- Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells (Q30412654) (← links)
- Antibody-based imaging of HER-2: moving into the clinic. (Q30423880) (← links)
- Use of64Cu-labeled Fibronectin Domain with EGFR-Overexpressing Tumor Xenograft: Molecular Imaging (Q30511916) (← links)
- Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab (Q33527397) (← links)
- Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. (Q33661325) (← links)
- Targeted radionuclide therapy with astatine-211: Oxidative dehalogenation of astatobenzoate conjugates. (Q33746975) (← links)
- PET of HER2 Expression with a Novel 18FAl Labeled Affibody (Q33776692) (← links)
- 'Image and treat': an individualized approach to urological tumors (Q33792596) (← links)
- In vivo targeting of HER2-positive tumor using 2-helix affibody molecules (Q34231627) (← links)
- Evaluation of the Anti-HER2 C6.5 Diabody as a PET Radiotracer to Monitor HER2 status and Predict Response to Trastuzumab Treatment (Q34694211) (← links)
- D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination (Q34718122) (← links)
- Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule (Q34775811) (← links)
- Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity (Q35571891) (← links)
- Optical Imaging with Her2-Targeted Affibody Molecules Can Monitor Hsp90 Treatment Response in a Breast Cancer Xenograft Mouse Model (Q35784634) (← links)
- A 45-Amino-Acid Scaffold Mined from the PDB for High-Affinity Ligand Engineering (Q35954982) (← links)
- 68Ga-DOTA-Affibody molecule for in vivo assessment of HER2/neu expression with PET (Q36085489) (← links)
- Molecular imaging of HER2-positive breast cancer: a step toward an individualized ‘image and treat’ strategy (Q36105964) (← links)
- Affibody-mediated PET imaging of HER3 expression in malignant tumours. (Q36174716) (← links)
- A fluorescent imaging method for analyzing the biodistribution of therapeutic monoclonal antibodies that can distinguish intact antibodies from their breakdown products (Q36215502) (← links)
- Towards detecting the HER-2 receptor and metabolic changes induced by HER-2-targeted therapies using medical imaging. (Q36324211) (← links)
- Alternative Non-Antibody Protein Scaffolds for Molecular Imaging of Cancer (Q37394193) (← links)
- Active targeting using HER-2-affibody-conjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors (Q37624379) (← links)
- Protein scaffold-based molecular probes for cancer molecular imaging (Q37696357) (← links)
- Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. (Q37776361) (← links)
- PET/CT in cancer research: from preclinical to clinical applications. (Q37784771) (← links)
- Molecular imaging: challenges of bringing imaging of intracellular targets into common clinical use (Q37985658) (← links)
- Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer (Q38088005) (← links)
- Design and evaluation of radiolabeled tracers for tumor imaging (Q38137253) (← links)
- Imaging EGFR and HER2 by PET and SPECT: a review (Q38137829) (← links)
- 64Cu-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor (Q38815325) (← links)
- Affibody molecules as engineered protein drugs (Q39197528) (← links)
- A kit to prepare 111In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer (Q39609841) (← links)
- Comparison of bifunctional chelates for (64)Cu antibody imaging (Q39692454) (← links)
- MR molecular imaging of HER-2 in a murine tumor xenograft by SPIO labeling of anti-HER-2 affibody (Q39742134) (← links)
- A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. (Q39743982) (← links)
- Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. (Q39841535) (← links)
- Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [(111)In]-labeled CHX-A″DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines (Q42018419) (← links)
- Positive progress in immunoPET--not just a coincidence (Q42429164) (← links)
- HSP90 expression and its association with wighteone metabolite response in HER2-positive breast cancer cells (Q42747804) (← links)
- A novel, smaller scaffold for Affitins: Showcase with binders specific for EpCAM. (Q47602824) (← links)
- Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe. (Q50326884) (← links)
- Aligning physics and physiology: Engineering antibodies for radionuclide delivery. (Q51740406) (← links)
- Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors. (Q55425539) (← links)
- Non-Antibody Scaffolds as Alternative Therapeutic Agents (Q57260221) (← links)
- Analytical applications of affibodies (Q58886398) (← links)